Join PDCI Market Access Inc.’s Nancy Paul Roc and Carla Freige at Québec’s International 11th edition of the Québec City Healthcare Industry Forum held on December 5 and 6, 2017 at the Hilton Québec.
As in previous editions, the 2017 Québec City Healthcare Industry Forum will spark discussions between stakeholders in ... Read More
27
Nov2017
16
Nov2017
On November 13, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a Notice to Manufacturers announcing further details on the continuous evaluation process.
As of December 1, 2017, manufacturers can submit an application for registration to INESSS for a new innovative drug product or a ... Read More
16
Nov2017
On November 13, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 130).
Revised Procedure for the CADTH Common Drug Review Resubmissions
In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements for its Common ... Read More
08
Nov2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017:
46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017:
Gazyva (obinutuzumab): Used to treat follicular lymphoma
Lynparza (olaparib): Used to treat ... Read More
08
Nov2017
On November 7, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the continuous evaluation process.
INESSS would like to inform manufacturers that as of November 1, 2017, new terms and conditions apply for manufacturers who wish to request ... Read More
03
Nov2017
On November 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) announced they have now published the list of drug products currently undergoing review under their new continuous evaluation process on their website.
Citizens, health professionals, patients and their caregivers, as well as their associations or ... Read More
01
Nov2017
The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2016. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of the prices of patented ... Read More
31
Oct2017
It is with great pleasure to announce after several months of a successful strategic partnership with Roubaix Strategies Inc. (RSI), John-Paul Dowson is formally joining the PDCI team as our new Director of Reimbursement Strategy.
John-Paul brings more than 20 years of senior experience working in the health and pharmaceutical sectors. ... Read More
30
Oct2017
We are pleased to announce that effective October 30, 2017 Jennifer Haig has joined PDCI Market Access Inc. as Manager, HTA and Health Economics.
Jen joins our growing HTA team and brings extensive experience with Pharmacoeconomic and Budget Impact modelling. Prior to joining PDCI, Jen was a market access and health ... Read More
18
Oct2017
The Régie de l’assurance maladie du Québec (RAMQ) released its October update of the List of Medications on October 18, 2017, effective immediately.
For more information and to see the list update schedule, please visit the RAMQ website.